Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

Martin, Paul; DiMartini, Andrea F.; Feng, Sandy; Brown, Robert S.; Fallon, Michael B.

doi:10.1002/hep.26972

Cited by 842 publications

(777 citation statements)

References 198 publications

(235 reference statements)

Supporting

Mentioning

752

Contrasting

Unclassified

Order By: Relevance

“…Potential postoperative pulmonary complications (POPC) of donors include pneumonia, atelectasis, pleural effusion, and pulmonary embolism. [8][9][10][11] Nowadays, liver transplant is the main treatment option with a better result of survival than other treatment methods for end-stage liver patients.…”

Section: Introductionmentioning

confidence: 99%

Postoperative Pulmonary Complications in Living-Liver Donors: A Retrospective Analysis of 188 Patients

Ulubay

Dedekarginoglu²,

Küpeli̇³

et al. 2015

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Living-donor liver transplant has become a viable option and an important source of hepatic grafts. The goal of this study is to establish postoperative pulmonary complications of liver donation surgery in our center. Materials and Methods: Data from 188 subjects (median age, 33.7 ± 8.4 y; male/female, 51.1%/48.9%) who had liver donation surgery from 1988 to 2013 were analyzed retrospectively. Patient demographic and clinical features were recorded. Postoperative complications and the correlation of risk factors for postoperative pulmonary complications were investigated. Results: The incidence of early postoperative complications was 17% (n = 32), and 16 of these patients had postoperative pulmonary complications (8.5%); 2 of the postoperative pulmonary complications were detected on the day of surgery and the other 14 complications were observed between the second and seventh day after surgery. Most postoperative pulmonary complications were minor complications including atelectasis, pleural effusion, and pneumonia. There was 1 major postoperative pulmonary complication: pulmonary embolism that occurred on the fourth day after surgery in 1 patient. Late pulmonary complications also were reviewed and no late postoperative pulmonary complications were observed. There was no significant difference in early and late postoperative pulmonary complications between ex-smokers and smokers. Postoperative atelectasis was significantly higher in patients with body mass index ≤ 20 kg/m² than patients with body mass index > 21 kg/m² (P = .027). In our study population, no postoperative mortality was recorded. Conclusions: We believe that preoperative weight reduction strategies and early mobilization with postoperative respiratory physiotherapy could be important factors to reduce postoperative pulmonary complications in liver donors.

show abstract

Section: Introductionmentioning

confidence: 99%

Postoperative Pulmonary Complications in Living-Liver Donors: A Retrospective Analysis of 188 Patients

Ulubay

Dedekarginoglu²,

Küpeli̇³

et al. 2015

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…We read with great interest the article by Holmes et al 1 published in HEPATOLOGY. The researchers conclude that inosine triphosphatase (ITPase) deficiency protects against ribavirin (RBV)-induced anemia, but that it is not associated with sustained virological response (SVR) to pegylated interferon (Peg-IFN)-a-2a/ RBV therapy in HCV genotype 1 (HCV-1)-infected patients from the CHARIOT study.…”

Section: Association Between Response To Pegylated Interferon/ribavirmentioning

confidence: 99%

“…2,3 We wonder whether RVR (32.8%) had any effect on the result of the association between SVR and hemoglobin decline or upon RBV pharmacokinetics in the study by Holmes et al 1 It is known that plasma RBV levels at week 8, rather than the actual hemoglobin levels or ITPase deficiency in patients with HCV-1 1 and genotype 2/3 infection, 1,4 have been associated with SVR. Since the very important role of the genetic variation in interleukin (IL)28B on predicting response to Peg-IFN-based therapies either without 3,5,6 or with new direct antiviral agents 7 has been recognized, it seems also necessary to take the IL28B genotype into consideration in elucidating the influence of RBV levels on SVR in HCV-1 patients, without otherwise detracting from the results by Holmes et al …”

Section: Association Between Response To Pegylated Interferon/ribavirmentioning

confidence: 99%

Indications for liver transplant and AASLD guidelines

Thapar

Bonkovsky

2014

Hepatology

View full text Add to dashboard Cite

“…Screening tests, according to age and risk factors, must include the exclusion of any disseminated cancer or local aggressive malignancy [3,4]. In order to minimize the chance of cancer relapse after LT, a 5-year disease free interval is recommended in those patients with history of extra hepatic neoplasm.…”

Section: Introductionmentioning

confidence: 99%